Patents by Inventor Caleb R. GLASSMAN

Caleb R. GLASSMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230220031
    Abstract: The present disclosure relates generally to compositions and methods for modulating signal transduction mediated by interleukin-12 and interleukin-23. In particular, the disclosure provides novel variants of interleukin-12 subunit p40 with reduced binding affinity to IL-12R?1. Also provided are compositions and methods useful for producing such IL-12p40 polypeptide variants, as well as methods for modulating IL-12p40-mediated signaling, and/or for the treatment of conditions associated with perturbations of signal transduction mediated by IL-12p40.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 13, 2023
    Inventors: Kenan Christopher GARCIA, Caleb R. GLASSMAN
  • Publication number: 20210269498
    Abstract: Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2R?. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.
    Type: Application
    Filed: May 13, 2021
    Publication date: September 2, 2021
    Inventors: Kenan Christopher GARCIA, Sonia S. MAJRI, Caleb R. GLASSMAN, Leon Lih-Ren SU
  • Publication number: 20200299349
    Abstract: Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2R?. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.
    Type: Application
    Filed: November 20, 2018
    Publication date: September 24, 2020
    Inventors: Kenan Christopher GARCIA, Sonia S. MAJRI, Caleb R. GLASSMAN, Leon Lih-Ren SU